Yusuke Yano
Takatsuki, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder Injury.
Journal: Oncology
Published: November 04, 2023
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
Journal: World journal of urology
Published: May 30, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Journal: Clinical genitourinary cancer
Published: March 24, 2023
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Journal: Cancer diagnosis & prognosis
Published: February 10, 2023
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Journal: Cancers
Published: October 18, 2022
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer.
Journal: In vivo (Athens, Greece)
Published: October 08, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Journal: BJU international
Published: September 13, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.
Journal: Clinical and translational radiation oncology
Published: August 26, 2022
Unplanned hemodialysis initiation and low geriatric nutritional risk index scores are associated with end-stage renal disease outcomes.
Journal: Scientific reports
Published: December 22, 2021
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
Journal: Journal for immunotherapy of cancer
Published: December 07, 2021
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Journal: Urologic oncology
Published: October 30, 2021
Last Updated: 09/26/2026